Troglitazone and pioglitazone were developed as thiazolidinedione-type antidiabetes drugs, but only troglitazone was withdrawn from the markets due to severe liver injury. As both troglitazone and its sulfate metabolite are strong inhibitors of the bile salt export pump (BSEP), troglitazone-induced bile acid (BA) retention is thought to be one of the underlying mechanisms of liver injury. However, pioglitazone is also a strong BSEP inhibitor, indicating other mechanisms may also be involved in troglitazone-induced BA retention. Although retention of hydrophobic BAs (eg, chenodeoxycholic acid [CDCA]: a nonamidated BA) is known to cause hepatocyte injury, little is known about the hepatic conversion of nonamidated, hydrophobic BA species into less toxic hydrophilic BAs (eg, glycochenodeoxycholic acid: amidated BA) as a mechanism of drug-induced liver injury. In this study, we, therefore, investigated the effects of troglitazone and pioglitazone on BA amidation and the role of amidated BAs in troglitazone-associated BA-mediated hepatotoxicity. We also evaluated the intracellular BA composition of human hepatocytes treated with nonamidated BA species (CDCA or deoxycholic acid [DCA]) in the presence of troglitazone or pioglitazone. Amidation of CDCA and DCA was significantly inhibited by troglitazone (IC 50 : 5 and 3 mmol/l, respectively), but not pioglitazone. Moreover, treatment with troglitazone led to the retention of CDCA and DCA and decrease of glycine-amidation in hepatocytes. From these results, we suggest that troglitazone-induced liver injury might be caused by the accumulation of nonamidated BAs in hepatocytes due to inhibition of BA amidation.
Drug-induced liver injury (DILI) is the most common reason for dropout of candidate compounds from clinical development and withdrawal from the marketplace. Therefore, elucidating the mechanisms of DILI and establishing useful methods for the evaluation of the DILI potential of new drug entities are critically important issues for the pharmaceutical industry.
Troglitazone (TRO) was the first thiazolidinedione antidiabetic agent approved for clinical use, but it was withdrawn in 2000 due to serious idiosyncratic liver toxicity. Many groups have investigated the mechanism of TRO-induced liver injury, and several mechanisms have been proposed such as reactive metabolite formation, mitochondrial toxicity, oxidative stress, etc. (Bova et al., 2005; Kassahun et al., 2001; Narayanan et al., 2003) . However, the overall mechanism remains unclear.
The bile salt export pump (BSEP), expressed on the canalicular membrane, is essential for bile acid (BA) transport from hepatocytes to the bile canaliculus (Meier and Stieger, 2002) . Therefore, it is thought that BSEP inhibition causes BA accumulation in hepatocytes, eventually leading to hepatotoxicity. BAmediated toxicity was also reported as one of the mechanisms of TRO-induced liver injury (Funk et al., 2001b) . In line with this finding, TRO and its sulfate were shown to inhibit ATPdependent taurocholate transport mediated by BSEP (Dawson et al., 2012; Funk et al., 2001a; Morgan et al., 2013) .
Pioglitazone (PIO) is a prescription drug for treating diabetes and in the same thiazolidinedione class as TRO. After its approval for clinical use in 1999, PIO was prescribed worldwide. Although BSEP inhibition by PIO (IC 50 0.3-0.4 lM) is about 10 times that by TRO (IC 50 2.7-3 mmol/l) (Dawson et al., 2012; Morgan et al., 2013) , no severe hepatotoxicity has been associated with PIO therapy. In this regard, mechanisms other than BSEP inhibition may also contribute to TRO-induced liver injury.
More than 10 BA species are present in human serum (Scherer et al., 2009) . BA lipophilicity is thought to be an important determinant of cytotoxicity. Nonamidated BAs, eg, chenodeoxycholic acid (CDCA), are more hydrophobic than amidated BAs, eg, glycochenodeoxycholic acid (GCDCA) (Chiang, 2009) . Indeed, the cytotoxicity of CDCA in HET-1A (a human oesophageal squamous epithelial cell line) and Huh7 (a human hepatoma cell line) is stronger than that of GCDCA (Sharma et al., 2010) . Nonamidated hydrophobic BA species (eg, cholic acid [CA] and CDCA) are derived from cholesterol by a cascade of enzymes including CYP7A1. These hydrophobic BA species are converted to hydrophilic BA species by conjugation with glycine or taurine in hepatocytes (Chiang, 2009) . Bile acid-CoA ligase (BAL) and bile acid-CoA: amino acid N-acyltransferase (BAT) are the enzymes responsible for BA amidation (Chiang, 2009; Shonsey et al, 2005a,b) . Therefore, an increase in the concentration of nonamidated BA species in hepatocytes due to drugrelated inhibition of these enzymes might contribute to the pathogenesis of BA-mediated hepatotoxicity.
Although BA transporter inhibition by drugs have been well investigated (Dawson et al., 2012; Kö ck et al., 2014; Morgan et al., 2013) , the importance of BA amidation inhibition by drugs has remained unclear. Therefore, we hypothesized that druginduced inhibition of BA amidation and BA transport might be an important factor in BA-mediated toxicity. To examine this hypothesis, we investigated the intracellular BA composition in human hepatocytes treated with TRO or PIO and whether TRO inhibits the formation of amidated BAs in human liver S9 fraction. Our current results indicate that BA amidation plays a critical role in the BA-mediated hepatotoxicity of TRO.
MATERIALS AND METHODS
Materials. BAs, TRO, and PIO were purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan), Sigma-Aldrich Japan (Tokyo, Japan), and Cosmo Bio Co., Ltd. (Tokyo, Japan). Cryopreserved hepatocyte recovery medium (CHRM), William's E medium (WEM), L-glutamine, penicillin-streptomycin, and insulin were purchased from Life Technologies Japan (Tokyo, Japan). Fetal bovine serum was obtained from MP Bio Japan (Tokyo, Japan). Matrigel and BioCoat collagen type 1 plates were purchased from Corning (Corning, New York). Pooled cryopreserved human hepatocytes and pooled human liver S9 were purchased from Sekisui Xenotech (Kansas City, Kansas). In addition, d 5 -taurocholate sodium was purchased from Toronto Research Chemicals (Toronto, Canada). BSEP-expressing membrane vesicles were purchased from SOLVO Biotechnology (Budaö rs, Hungary). All other chemicals and solvents were of analytical grade.
Membrane vesicles assay. BSEP-expressing membrane vesicles were harvested from Sf9 insect cells. The assay followed the Solvo assay protocol (refer to the Solvo assay protocol for details Human hepatocyte culture. Cryopreserved human hepatocytes were dispersed in prewarmed (37 C) CHRM, and centrifuged at 100 g for 10 min. The cell pellets were then resuspended in WEM containing 5% fetal bovine serum, 100 U/ml penicillin, 100 lg/ml streptomycin, 4 mg/l insulin, 1 mmol/l dexamethasone and 2 mmol/l L-glutamine. Hepatocyte viability was determined to be >90% by trypan blue exclusion. The hepatocyte suspensions were then added to 48-or 96-well BioCoat plates at density of 2.0 Â 10 5 cells/cm 2 .
Approximately 4 h after plating, sandwich cultures were initiated by overlaying the hepatocyte monolayer with Matrigel (0.3 mg/ml) dissolved in ice-cold WEM containing 100 U/ml penicillin, 100 lg/ml streptomycin, 4 mg/l insulin, 0.1 mmol/l dexamethasone, and 2 mmol/l L-glutamine, and maintaining culture conditions (37 C, humidified atmosphere of 95% air and 5%
CO 2 ) with daily change of the medium. All experiments were conducted 3 days after cell seeding.
Bile acid accumulation in human hepatocytes. On Day 4 of culture, the medium was aspirated from each well and replaced with medium containing TRO or PIO (5 and 50 mmol/l) and CDCA or DCA (5 mmol/l). TRO and PIO were solubilized in dimethylsulfoxide (DMSO) and then diluted in WEM (0.1% [v/v] DMSO). Vehicle alone served as the control. Hepatocytes were incubated at 37 C for 0.5 or 8 h, washed with ice-cold Hanks' balanced salt solution 3 times after removal of the spent medium, and then stored in a freezer until liquid-chromatography-tandem mass spectrometry (LC-MS/MS) analysis.
Sample preparation from hepatocytes for LC-MS/MS analysis. The frozen plate was thawed to room temperature before sample preparation, incubated with 1N NaOH (100 ll per well) for 0.5 h, and then neutralized by 1N HCl (100 ll per well). Each cell lysate was moved to 1.5 ml tubes for determination of BA concentration, mixed with 200 ll of methanol containing 15 ng/ml d 5 -taurocholate sodium (internal standard), shaken for about 30 s, and centrifuged at 20 400 g for 10 min. The corresponding supernatants were filtered through Captiva 96-well 0.45-mm polyvinylidene fluoride (PVDF) filter plates (Agilent, Santa Clara, California), collected into 96-well plates, and assayed for CDCA, DCA, GCDCA, and glycodeoxycholic acid (GDCA) by LC-MS/MS. For preparation of the calibration standard, we used saline as the blank matrix since hepatocytes contain endogenous GCDCA. Protein concentrations were determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific, Waltham, Massachusetts)
Effect of troglitazone and pioglitazone on the conjugation of BAs with amino acids in the S9 fraction. The amidation reaction of BAs with glycine was performed as previously reported with slight modification (Shonsey et al., 2005a,b) . The assay mixture contained 50 mmol/l phosphate buffer (pH 7.4), 10 mmol/l glycine, 50 mmol/ l coenzyme A, 5 mmol/l ATP, 5 mmol/l MgCl 2 , 5 mmol/l dithiothreitol, 0-10 mmol/l TRO or PIO, and 0.5 mg protein/ml human liver S9 LC-MS/MS analysis of BAs. Analysis of prepared samples was performed using an LC-MS/MS system consisting of a Shimadzu LC 20A (Shimadzu, Kyoto, Japan) coupled to a QTRAP 5500 spectrophotometer (AB Sciex, Framingham, Massachusetts) using a Hydrosphere C18 column (75 Â 2.0 mm. 5 mm, YMC, Kyoto, Japan). Mobile phases A and B were 10 mmol/l ammonium acetate (pH not adjusted) and 100% methanol, respectively. The mobile phase gradient was as follows: 0-0.5 min (50% mobile phase A), 0.5-1 min (a linear increase to 30% A), 1-3.5 min (30% A), 3.6-4.5 min (20% A), 4.6-5.5 min (10% A), and 5.6-6.5 min (re-equilibration to 50% A). The retention time and monitored ions of each BA are listed in Table 1 .
Cytotoxicity assay. Hepatocytes were exposed to TRO or PIO (25 mmol/l) with or without 5-200 mmol/l CDCA or DCA for 24 h and assayed to measure cytotoxicity using the LDH-Cytotoxic Test (Takara Bio Inc., Shiga, Japan) in accordance with the manufacturer's protocol.
Data analysis. IC 50 was calculated by fitting the data to the equation shown below using a pharmacokinetic analysis software Phoenix WinNonlin ver. 6.3 (Certara, Princeton, New Jersey).
The data obtained were analyzed by 1-way ANOVA followed by the Tukey's test and P < .05 was considered as the level of significance.
RESULTS
Inhibitory Effect of TRO or PIO on Bile Acid Transporter TRO and PIO are reported to inhibit BSEP (Dawson et al., 2012; Morgan et al., 2013) . To confirm the inhibitory effect of TRO and PIO for BSEP in our laboratory, a transport assay using BSEPexpressing vesicles was conducted. TRO and PIO inhibited the BSEP activity in a concentration-dependent manner. The IC 50 values of TRO and PIO were 2.1 and 0.12 mmol/l, respectively (Figure 1) . The inhibitory potency of PIO was about 20 times that of TRO.
Composition of Amidated and Nonamidated Bile Acids in Hepatocytes
Sandwich cultured hepatocytes (SCHs) are distinctive from hepatocytes cultured under conventional conditions in that they maintain cell polarity and express transporters or metabolic enzymes (Swift et al., 2010) , and thus are thought to be an in vitro model that better reflects hepatocyte functional activity in vivo. Therefore, we employed SCH for this study. To investigate the effect of the incubation-time dependency of each BA species on intracellular BAs composition, two incubation periods (0.5 and 8 h) were used. We monitored only the amount of glycine-conjugated CDCA or DCA because the amount of taurine conjugates in hepatocytes was negligible.
Endogenous GCDCA, but not CDCA, DCA, and GDCA, could be detected in hepatocytes. The intracellular amount of CDCA was decreased by TRO and PIO treatments for 0.5 h at all concentrations except 50 mmol/l TRO (Figure 2a) . After 8 h incubation, TRO at 50 mmol/l significantly increased the intracellular amount of CDCA (Figure 2b ) and decreased the intracellular amount of GCDCA (Figure 2d ). The fluctuation in intracellular DCA and GDCA (Figure 3 ) was similar to that in intracellular CDCA and GCDCA.
To evaluate the effect of TRO and PIO treatment on formation of amidated BAs after uptake into hepatocytes, we calculated the ratio of amidated BAs to nonamidated BAs. The ratio after 0.5 h incubation is shown in Figure 4 , and the GCDCA/ CDCA and GDCA/DCA ratios in the control group were 1.8 and 8.8, respectively. TRO significantly decreased the GCDCA/CDCA ratio (5 mmol/l: 1.44, 50 mmol/l: 0.44) and GDCA/DCA ratio (5 mmol/l: 5.25, 50 mmol/l: 0.88); on the other hand, PIO slightly decreased the ratio at 50 mmol/l (GCDCA/CDCA: 1.55, GDCA/ DCA: 7.04) but not at 5 mmol/l. The effects of TRO treatment on the GCDCA/CDCA and GDCA/DCA ratios were greater than those of PIO.
Inhibition of Bile Acid Amidation by TRO
Most of the BAs in the body are glycine-or taurine-amidated (Baptissart et al., 2013) . BA amidation in the liver is catalyzed by 2 enzymes, BAL and BAT, in a 2-step reaction (Chiang, 2009; Shonsey et al., 2005a,b) . Intrahepatic nonamidated BA species are first converted into their coenzyme A thioesters by BAL in microsomes. Subsequently, these intermediates are converted to amidated BAs by cytosolic BAT (Solaas et al., 2000; Styles et al., 2007; Wheeler et al., 1997) . Therefore, we evaluated the inhibitory effect of TRO and PIO on amidation of CDCA and DCA using human S9 fraction. The data showed that TRO but not PIO inhibited the amidation of CDCA and DCA in a concentrationdependent manner, respectively ( Figure 5 ). PIO (up to 100 mmol/ l) did not inhibit the amidation (data not shown). The calculated IC 50 values for the inhibition of CDCA or DCA amidation by TRO were 5.4 and 3.2 mmol/l, respectively. Cytotoxicity Induced by TRO or PIO Treatment in the Presence of BA Drug-induced cytotoxicity due to accumulation of BAs in hepatocytes can be evaluated in SCH co-treated with both drug and BAs (Ogimura et al., 2011) . Therefore, we investigated whether TRO and PIO caused BA-dependent cytotoxicity using this model. Maximum concentration of CDCA and DCA was fixed at their half maximal cytotoxic concentrations (200 mmol/; CC 50 for both CDCA and DCA in Het-1A that does not express BAL and BAT) (Sharma et al., 2010) . No TRO-or PIO-induced cytotoxicity was detected in the absence of CDCA or DCA (Figure 6 ). The PIO-CDCA or -DCA combination did not cause cytotoxicity. On the other hand, hepatocytes treated with CDCA or DCA were susceptible to TRO-induced cytotoxicity in BA-concentrations dependent manner (Figure 6 ). Notably, Tro significantly enhanced the cytotoxicity induced by as low as 5 mmol/l CDCA and DCA. 
DISCUSSION
We confirmed the inhibitory effect of TRO and PIO on BSEPmediated transport using value of TRO sulfate is 0.4-0.6 mmol/l and about one-tenth the IC 50 value of TRO (3.9 mmol/l).
The maximum concentration in circulating plasma (C max ) of TRO, TRO sulfate, and PIO in humans is 3.17, 9.78, and 5.33 mmol/l, respectively (Prueksaritanont et al., 2001; Young et al., 1998 ; Japanese interview form). The ratio of C max to IC 50 is employed for evaluation of drug interaction potential with transporter (US FDA et al., 2012) . The calculated C max /IC 50 ratios for TRO, TRO sulfate (using IC 50 for rat Bsep as surrogate), and PIO are 1.51, 24.5, and 44.4, indicating that PIO is the strongest of the 3 inhibitors of human BSEP function. However, the cytotoxicity of PIO in the presence of BAs was weaker than that of TRO ( Figure 6) . Collectively, these observations may imply that TRO-induced BAmediated liver toxicity cannot be explained by only BSEP inhibition. Therefore, we hypothesized that not only BSEP inhibition but also other mechanisms might be involved in the pathogenesis of the BA-mediated toxicity of TRO.
To investigate the effect of TRO and PIO on intracellular BAs composition, we measured BAs in human hepatocytes incubated with CDCA or DCA (5 mmol/l) in the presence of TRO or PIO (Figs. 2-4 ). As summarized in Table 2 , both TRO and PIO inhibit not only BSEP but also other BA transporters, indicating intracellular concentration of nonamidated and amidated BAs might be affected in complex ways. In fact, TRO and PIO inhibit Na þ -dependent taurocholate cotransporting polypeptide (NTCP) (Dong et al., 2014; Marion et al., 2007) . At the concentrations of TRO and PIO tested in this study, NTCP could be inhibited strongly (Table 2) . However, the intracellular CDCA and DCA levels in hepatocytes after 0.5 h of incubation with these BAs were not much decreased (Figs. 2a and  3a) . It is suggested that passive diffusion and other uptake transporters (eg, organic anion-transporting polypeptides) may largely contribute to the distribution of hydrophobic BAs such as CDCA and DCA within hepatocytes and thus to their almost unchanged intracellular levels. When compared with hydrophilic BA (ie, GCDCA and GDCA), the contribution of passive diffusion to the uptake of hydrophobic BAs (ie, CDCA and DCA) is thought to be greater than active transport. The intracellular increase (accumulation) in CDCA and DCA provoked by TRO (Figs. 2b and 3b) was thought to be difficult to consider from only transporter inhibition mechanisms. After uptake into hepatocytes, CDCA and DCA can undergo amino acid conjugation and/or excretion by transporters. Multidrug resistanceassociated protein 3 (MRP3) and MRP4 are known to transport BAs from hepatocytes to blood and decrease intracellular BA level (Kö ck et al., 2014; Rius et al., 2006) , indicating that amidated CDCA and DCA are excreted into the medium. TRO and PIO are reported to be weak inhibitors of MRP3 and MRP4 (Table 2 ). After 8 h of incubation, CDCA and DCA had significantly accumulated in hepatocytes treated with TRO (50 mmol/l) (Figs. 2b  and 3b ). In contrast, the intracellular GCDCA and GDCA levels were reduced in the presence of TRO and PIO (Figs. 2d and 3d) . If MRPs were inhibited by TRO and PIO, GCDCA and GDCA would also accumulate in hepatocytes, suggesting that the contribution of MRPs to the intracellular increase in CDCA and DCA was probably negligible. GCDCA and GDCA excreted by MRP3 and/or MRP4 into the medium could be taken up again by NTCP. As mentioned earlier, PIO could be inhibited NTCP at the concentrations tested in this study. Therefore, it is suggested that the inhibition of GCDCA or GDCA reuptake from the medium is a reason that the intracellular amounts of GCDCA or GDCA were decreased by pioglitazone without inhibition of BA amidation.
In this study, BAs in hepatocytes and those in bile canalicular pockets were not measured separately. Therefore, the measured values of BAs were a combination of BA levels in cells and the bile canalicular pockets. Marion et al. (2011) (Figs. 2b and 3b ). From such points of information, we hypothesized that the increase in intracellular accumulation of nonamidated BAs (CDCA and DCA) induced by TRO is due to inhibition of BA amidation. BA amidation is catalyzed in a 2-step reaction by BAL and BAT (Chiang, 2009; Shonsey et al., 2005a,b) . Gene mutations leading to deficiency of BAL and BAT are known to cause cholestasis, malabsorption of fat-soluble vitamins, and growth retardation due to decreased levels of amidated BAs (Chong et al., 2012; Had zi c et al., 2012) . As shown in Figure 5 , TRO inhibited CDCA and DCA amidation in a concentration-dependent manner and their IC 50 values were 5.4 mmol/l (CDCA) and 3.2 mmol/l (DCA). Vessey and Kelley (1995) reported that cyclosporine inhibits BAL, the rate-limiting enzyme of BA amidation (Solaas et al., 2000) and the enzyme that catalyzes the first step in BA amidation. Therefore, it is suggested that BAL might play an important role in the drug-induced inhibition of BA amidation. However, information regarding the inhibition of BA amidation by drugs is very limited. Therefore, whether certain drugs inhibit BA amidation should be investigated in the future.
CDCA (CC 50 : 216 mmol/l) and DCA (CC 50 : 257 mmol/l) are more cytotoxic than GCDCA (CC 50 : > 500 mmol/l) and GDCA (CC 50 : > 500 mmol/l) in HET-1A (a human oesophageal squamous epithelial cell line) (Sharma et al., 2010) . In the preliminary studies, CDCA and DCA required higher concentrations to cause toxicity in hepatocytes (data not shown). As shown in Figures 2 and 3 , CDCA and DCA are promptly amidated to GCDCA and GDCA in hepatocytes, respectively, indicating that the toxicity of CDCA and DCA is inevitably attenuated by amidation. Even if CDCA and DCA are exposed to hepatocytes, they undergo amidation, thus it is difficult to distinguish whether the hepatocytes toxicity is induced by CDCA (DCA) or GCDCA (GDCA). Considering these points, we quoted the cytotoxicity data obtained in nonhepatic cell that does not express BAL and BAT, since it seemed suitable to separately compare the toxicity of CDCA (DCA) and Dong et al. (2014) . its glycine-amidate. As shown in Figure 6 , TRO showed significant toxicity in hepatocytes only in the presence of BAs. On the other hand, in the presence of CDCA or DCA, PIO-induced cytotoxicity was absent. BA is known to induce reactive oxygen species and mithochondrial damage, resulting hepatocytes death through apoptosis and necrosis (Perez and Briz, 2009) . BAs accumulation in hepatocytes by TRO would have caused the cytotoxicity through such a mechanism.
Tro significantly enhanced the hepatocytes toxicity induced by as low as 5 mmol/l CDCA and DCA (Figure 6 ). Such BA concentrations used in our cytotoxicity assay are not far beyond those under pathophysiological condition. Serum BA concentrations in healthy human are 2-5 mmol/l, while that in patients with liver disease are 6-600 mmol/l (Davit-Spraul et al., 2010; Keitel et al., 2005; Scherer et al., 2009; Taegtmeyer et al., 2014) , indicating that BA concentration varies dynamically especially in the patients. Regarding the individual BA, CDCA is known to elevate up to 80 mmol/l in patients with liver disease (Taegtmeyer et al., 2014) . In addition, Lindblad et al. (1977) reported that the BA concentration gradient among systemic serum, portal serum, liver tissue, and hepatic bile was 1:3:80:2600 in human with normal liver function. Thus, the concentration of BA in human varies greatly among the compartments as well as among individual patients. Therefore, there is a possibility that BA concentration in the liver tissue is increased in certain patients and BAamidation inhibitors such as TRO may eventually contribute to the pathogenesis of liver injury in an idiosyncratic manner.
The IC 50 values for inhibition of CDCA and DCA amidation by TRO were 3-5 mmol/l, while the inhibitory potential of PIO was not the same ( Figure 5 ). BSEP is known to have a higher affinity for amidated BAs than nonamidated BAs (Hayashi et al., 2005) . Therefore, BSEP may not contribute much to the clearance of CDCA and DCA from hepatocytes. Taking these considerations into account, it would seem that inhibition of BA amidation by TRO augments CDCA and DCA accumulation in hepatocytes, resulting in cell toxicity (Figure 7) , whereas PIO strongly inhibits BSEP without inhibiting BA amidation. That may explain why severe hepatotoxicity has not been reported in PIO.
To our knowledge, this study is the first to report that TRO inhibits BA amidation. Use of a dual inhibitor of both BA amidation enzymes and BSEP, such as TRO, may carry a high risk of BA-mediated hepatotoxicity. Although more detailed studies are necessary to directly show causality of inhibition of BA amidation and hepatocytes toxicity, it is suggested that the inhibition of BA amidation is a novel mechanism and one of the risk factors for DILI.
